Filing Flows › Fulgent Genetics (FLGT) › Q3 2026 › vs Q3 2025
Fulgent Genetics (FLGT) Q3 2026 vs Q3 2025 (year over year)
Fulgent Genetics's revenue rose $6.3M (+8%) from $84.1M in Q3 2025 to $90.4M in Q3 2026.
Fulgent Genetics, Q3 2026: revenue $90.4M (+8% year over year), operating margin -24.9%, net loss $13.3M, operating cash flow $109M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Free cash flow margin | 118.8% | 6.0% | +112.8 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $90.4M | $84.1M | $6.3M | +8% |
| Other income, net | $8.5M | $7.8M | $663K | +8% |
| Income tax benefit | $704K | $683K | $21K | +3% |
| Net loss | $13.3M | $6.8M | $6.5M | +95% |
| Costs & expenses | $113M | $99.4M | $13.5M | +14% |
| Operating costs | $113M | $99.4M | $13.5M | +14% |
| Cost of revenue | $58.5M | $48.6M | $9.9M | +20% |
| Research & development | $13.6M | $13.9M | −$224K | -2% |
| Sales & marketing | $15.6M | $11.6M | $4.0M | +34% |
| General & admin | $22.8M | $23.3M | −$574K | -2% |
| Other operating costs | $2.5M | $2.0M | $466K | +23% |
| Operating cash sources | $123M | $17.9M | $105M | +583% |
| Depreciation & amortization | $6.8M | $6.0M | $778K | +13% |
| Share-based compensation | $8.1M | $9.7M | −$1.6M | -16% |
| Working capital & other | $108M | $2.2M | $105M | 49× |
| Net loss absorbed | $13.3M | $6.8M | $6.5M | +95% |
| Operating cash flow | $109M | $11.1M | $98.1M | +883% |
| Free cash flow (OCF − capex) | $107M | $5.1M | $102M | 21× |
| Capital expenditures | $1.8M | $6.0M | −$4.3M | -70% |
Questions
How much did Fulgent Genetics's revenue grow year over year in Q3 2026?
Fulgent Genetics's revenue rose $6.3M (+8%) from $84.1M in Q3 2025 to $90.4M in Q3 2026.